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Objective: To determine whether metronidazole has an adverse effect on the growth of Lactobacillus.
Methods: Hydrogen peroxide- and bacteriocin-producing strains of Lactobacillus were used as test strains.
Concentrationsof metronidazole used ranged from 128 to 7000 mg/ml. Susceptibility to metronidazole was con-
ductedbythebrothmicrodilution methodrecommendedbythe NationalCommitteeforClinicalLaboratoryStan-
dards.
Results: Growth of Lactobacillus was partially inhibited at concentrations between 1000 and 4000 mg/ml
(p = 0.014). Concentrations‡ 5000 mg/ml completely inhibited growthof Lactobacillus. Concentrationsbetween
128 and 256 mg/ml stimulated growth of Lactobacillus (p = 0.025 and 0.005, respectively). Concentrations of
metronidazole between 64 and 128 mg/ml or ‡ 512 mg/ml did not have an inhibitory or a stimulatory effect on the
growth of Lactobacillus compared to the control.
Conclusions: High concentration of metronidazole, i.e. between 1000 and 4000 mg/ml, partially inhibited the
growth of Lactobacillus. Concentrations ‡ 5000 mg/ml completely suppressed the growth of Lactobacillus.
Concentrations between ‡ 128 and £ 256 mg/ml stimulated the growth of Lactobacillus. Further investigation to
determine the ideal concentrationof metronidazole is neededin orderto usethe antimicrobial agent effectively in
the treatment of bacterial vaginosis.
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Bacterial vaginosis (BV) is a clinical syndrome of
unknownetiology. It occurs when normal vaginal
flora is replaced by an overgrowth of Gardnerella
vaginalis and anaerobic microorganisms1. The
currenttherapeutic goalforBV isto reestablish the
normal vaginal flora2. Metronidazole, orally or
intravaginally, is the drug of choice recommended
bytheCenters forDisease ControlandPrevention
for treatment of BV2. However, after 1 month,
cure rates for both treatment regimens range from
60% to70%.These high failure rates seem to occur
because of an inability to reestablish the lacto-
bacilli-predominant vaginal flora after treatment3.
In a recent article, Paavonen and colleagues4
compared oral metronidazole to 3 days of clinda-
mycin ovules and achieved a 68% cure race4. Thus
neither metronidazole nor clindamycin appears to
be effective treatment for BV.
It is well established that metronidazole is
significantly active against anaerobes but is
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Clinical study 41not active against G. vaginalis and facultative
anaerobes5. Thereare relatively few publisheddata
on the effects of metronidazole on vaginal
lactobacilli. These published studies suggest that
metronidazole has no effect on lactobacilli6,7. This
study was conducted to assess the in vitro effect of
different metronidazole concentrations on the
growth of vaginal lactobacilli.
MATERIALS AND METHODS
Metronidazole activity was evaluated, in vitro,
against eight clinical strains of vaginal Lactobacillus.
These strains were recovered from women with
healthy vaginal microflora. Lactobacilli were
initially identified on the basis of the colony
morphology when grown on Mann–Rogosa–
Sharp (MRS) agar and the morphologic
appearance on Gram stain. A MicroLog Microbial
Identification System® (Biolog Inc., Hayward,
CA) was used to identify the following species:
Lactobacillus casei (four strains), L. acidophilus (three
strains) and L. jensenii (one strain). These bacteria
were maintained at 70°C in skim milk (Difco
Laboratories, Detroit, MI) prior to testing.
Susceptibility to metronidazolewas determined
bythebrothmicrodilutionmethod recommended
by the National Committee for Clinical Lab-
oratory Standards (NCCLS)8. MRS broth (Difco,
Becton Dickinson Microbiology Systems, Sparks,
MD) was prepared for use in this study. Fresh
subcultures of lactobacilli were used after
overnight growth on an MRS agar plate under
anaerobic conditions.The inoculumwas prepared
by suspending several of these colonies in sterile
phosphate-buffered saline (pH 7.2) to achieve a
turbidity of 0.5 McFarland standard, determined
by nephelometry. This resulted in a suspension
containing approximately 1–2 ´ 108 CFU/ml.
These suspensions were further diluted with
MRS broth to obtain a final inoculum suspension
of5–10´ 105 CFU/ml. They were then dispensed
to sterile microdilution test plates (Honeycomb
Microwell Plate®; Labsystems, Finland) prepared
with different concentrations of metronidazole
(Sigma Chemical Co., St. Louis, MO). After
the addition of Lactobacillus inocula, the final
range of metronidazole concentrations was
1–7000 mg/ml. The plates were overlaid with
sterile paraffin oil and incubated at 36°C in a
Bioscreen C Analyser System® (Labsystems) for 48
hours.
The optical density of each tested sample was
measured automatically at 4-h intervals on a wide
band. Statistical analyses were performed by the
Freidman test. The Mann–Whitney test was used
to compare the species of lactobacilli with respect
to the percentage of growth inhibition at different
concentrations of metronidazole.
RESULTS
The growth of Lactobacillus in the presence of
metronidazole depended on the concentration of
metronidazole. Growth was stimulated at concen-
trations between 128 and 256 mg/ml (p = 0.025
and 0.005, respectively; Figure 1). No statistically
significant differences were found between the
control and metronidazole concentrations of
512 mg/ml or £ 64 mg/ml.
Concentrations of 1000–4000 mg/ml had a
partial inhibition of growth (p = 0.014; Figure 2).
Concentrations of metronidazole ‡ 5000 mg/ml
showed complete inhibition of Lactobacillus
growth. The inhibitory effect of metronidazole
started at a concentration of l000 mg/ml and
was more intense at the higher concentrations
(Table 1). There was a statistically significantly
greater percentage of growthinhibitionfor L. casei
strains compared to L. acidophilus strains for a
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Figure 1 Median Lactobacillus growth in metro-
nidazole concentrations of 128 and 256 mg/mlmetronidazole concentration of 4000 mg/ml
(83.0 ± 11.0 vs 64.0 ± 4.5; p = 0.034).
Table 2 depicts the effect of varying metro-
nidazole concentrations on the species of
Lactobacillus tested. Concentrations ‡ 4000 mg/ml
were similar in their inhibitory effect on
the growth of Lactobacillus. Concentrations
‡ 3000 mg/ml were also similar, except for
L.acidophilus strain 117, whichdidnotappeartobe
affected to the same degree as the other strains and
species.
DISCUSSION
This study demonstrates that different metro-
nidazoleconcentrationscanhave a varied effect on
the growth of lactobacilli in vitro. Concentrations
< 512 mg/mlhaveatendencytostimulate growth.
However, at concentrations ‡ l000 mg/ml,
growth is inhibited. These findings may be perti-
nent to the current treatment of BV, particularly
with metronidazole intravaginal treatment.
The recommended regimens include metro-
nidazole 500 mg orally, twice per day for 7 days,
and metronidazole gel 0.75% (7.5 mg/g), one full
applicator (5 g, containing 37.51 mg of metro-
nidazole) intravaginally twice per day for 5 days2.
Cure rates 7–10 days after the oral regimen are
84% and after the vaginal regimen are 75%. After
1 month, however, the cure rates after
bothtreatment regimens are only60–70%,and the
BV recurrence rate is up to 20% after treat-
ment3,9,10. The reasons for the recurrence are not
understood.Onepossible explanation is thefailure
to reestablish the normal, and perhaps protective,
Lactobacillus-predominant vaginal flora following
therapy5.
Metronidazole,beingprimarily effective against
obligateanaerobicbacteria,isthoughtto havelittle
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Clinical isolate
Metronidazole concentration ( g/ml)
7000 6000 5000 4000 3000 2000 1000
L. acidophilus (29)
L. acidophilus (117)
L. acidophilus (160)
L. casei (30)
L. casei (102)
L. casei (66)
L. casei (130)
L. jensenii (135)
91.1
86.1
95.1
98.9
99.8
85.6
89.5
92.9
87.0
86.0
93.1
98.9
98.5
86.7
96.7
84.6
88.6
70.3
84.2
96.9
94.8
73.0
93.9
82.7
66.7
58.8
66.5
96.6
76.2
72.2
86.8
75.2
76.9
35.4
61.0
90.0
73.6
57.0
84.4
64.8
58.8
19.8
37.6
90.7
48.5
57.1
65.5
54.8
29.0
15.4
13.2
84.7
20.8
23.2
30.0
21.7
Table 2 Percentage of growth inhibition of Lactobacilli by high concentrations of metronidazole (after 24 h)
Metronidazole
concentration (µg/ml)
Optical density
Mean Standard deviation
0 (control)
128
256
1000
2000
3000
4000
1.66
1.67
1.64
1.28
1.02
0.86
0.70
0.38
0.45
0.49
0.50
0.40
0.33
0.32
Table 1 Lactobacillus optical density for different
metronidazole concentrations (after 24 h)
Figure 2 Median Lactobacillus growth in metro-
nidazole concentrations ranging from 1000 to
7000 mg/mleffect on the growth of the normal vaginal flora11.
The available data regarding the effect of metro-
nidazole on the growth of vaginal lactobacilli
suggest thatmetronidazolewouldbemost likelyto
preserve endogenous lactobacilli. Agnew and
Hillier6 found that treatment of women with BV
using oral or vaginal metronidazole led to
increased colonization by lactobacilli. However,
they also found that about half of the women
lacked vaginal lactobacilli H2O2 producersfollow-
ing treatment with metronidazole.
Another study showed that intravaginal metro-
nidazole gel 0.75% does not inhibit lactobacilli7.
However, the authors recovered lactobacilli
from only 65% of the women 1 month after
treatment. In the study performed by Bayer and
colleagues12, metronidazole was totally ineffective
against the lactobacilli. However, the maximal
concentration they tested was 320 mg/ml, based
on the generally achievable serum concentration
of 12.5 mg/ml after the administration of oral
metronidazole.
After vaginal administration of 37.5 mg (a 5 g
applicator dose) of 0.75% metronidazole gel, the
maximal serum concentration was 0.2 mg/ml13,
whereas vaginal concentrations of the drug may
reach levels of 1000 mg/ml (Curatek Pharma-
ceuticals, Elk Grove, IL). Little information on
vaginal concentration after oral metronidazole
dosing is available. However, one study found a
vaginal concentrationof only 26 mg/ml 6 h after a
2 g oral dose14.
This study demonstrates that high concen-
trations (‡ 1000 mg/ml) of metronidazole can
inhibit the growth of vaginal lactobacilli in vitro. It
is important to determine the lowest effective dose
of vaginal metronidazole against BV in order to
reduce the incidence of side-effects15. Livengood
and colleagues16 recently showed that once-
per-day dosing of 0.75% metronidazole gel has
an efficacy equivalent to that of the currently
used twice-per-day dosing in the treatment of
BV. These authors suggested that such modifi-
cation would improve the regimen by decreasing
the total amount of metronidazole required.
Further studies are needed to determine whether
lower vaginal doses of £ 512 mg/ml are efficacious
in treating BV and restoring Lactobacillus to a
dominant role.
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